AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes

Published:2017-01 Issue: Volume:45 Page:36-44.e2
ISSN:0301-472X
Container-title:Experimental Hematology
language:en
Short-container-title:Experimental Hematology

Author:

An Xiaoyu,Liu Jinping,Wang Na,Wang Di,Huang Liang,Zhang Likun,Cai Jie,Wery Jean-Pierre,Zhou Demin,Zhou Jianfeng,Li Qi-Xiang

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Genetics,Hematology,Molecular Biology

Reference25 articles.

1. Role of FLT3 in leukemia;Gilliland;Curr Opin Hematol,2002

2. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia;Nakao;Leukemia,1996

3. Mutant FLT3: A direct target of sorafenib in acute myelogenous leukemia;Zhang;J Natl Cancer Inst,2008

4. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia;Smith;Nature,2012

5. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML);Zarrinkar;Blood,2009

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models;Scientific Reports;2024-04-19

2. Corrigendum to “AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes” [Experimental Hematology 2017;45:36–44];Experimental Hematology;2021-01

3. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD+ acute myeloid leukemia;Signal Transduction and Targeted Therapy;2020-03-13

4. In Vivo Pharmacology Models for Cancer Target Research;Target Identification and Validation in Drug Discovery;2019

5. Protein kinase inhibitors for acute leukemia;Biomarker Research;2018-02-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3